Oprozomib, a tripeptide epoxyketone, is an orally active and irreversible inhibitor of 20S proteasome, targeting primarily chymotrypsin-like activity. It inhibits growth and induces apoptosis in MM (multiple myeloma) cells resistant to conventional and bortezomib therapies. Its anti-MM activity is associated with activation of caspase-8, caspase-9, caspase-3, and poly(ADP) ribose polymerase, as well as inhibition of migration of MM cells and angiogenesis.

KEYWORDS: Oprozomib | Supplier | Proteasome inhibitor | ONX-0912 | PR-047 | ONX0912 | ONX 0912 | PR047 | PR 047 | CT-OPRO | CAS [935888-69-0] | Non Selective (Ubiquitin peptides) | Proteasome 20S | Inhibitor | Enzymes